Self-determination Plus Instant Messaging for Smokers With Cancer
Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 7, 2022
Trial Information
Current as of February 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people with cancer who smoke to quit smoking. The researchers want to see if allowing participants to choose their own quit schedule, along with receiving regular instant messages about quitting, will help them stop smoking more effectively than just giving them advice to quit right away. The trial will involve nearly 1,450 smokers with cancer, who will be recruited from outpatient clinics in Hong Kong.
To be eligible, participants need to be at least 18 years old, have smoked weekly for the last six months, and have been diagnosed with any stage of cancer for at least six months. They should also be able to communicate in Cantonese and use a smartphone for instant messaging. Those who join the study will receive either personalized support and messaging or standard advice to quit smoking immediately, along with helpful pamphlets. This study aims to find out which approach is more effective in helping smokers with cancer quit successfully.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • smoked weekly in the last 6 months,
- • diagnosed with any cancer for at least 6 months and at all cancer stages (I, II, III, or IV),
- • aged 18 years or above and can communicate in Cantonese, and
- • own a smartphone and able to use instant messaging (e.g. WhatsApp or WeChat)
- Exclusion Criteria:
- • individuals with unstable medical conditions, poor cognitive state, or mental illness as advised by the doctor in charge and noted on their medical records, and
- • those participating in other smoking cessation programmes.
Trial Officials
Ho Cheung William Li, PhD
Principal Investigator
Chinese University of Hong Kong
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials